Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Veligrotug in Thyroid Eye Disease (TED) with Recurrence After Teprotumumab
NCT07832136Phase 4Not yet recruiting
- Sponsor
- Viridian Therapeutics
- Start
- Sep 2026
- Primary completion
- Apr 2027
- Countries
- 1
01
Overview
A Phase 4 trial of veligrotug in thyroid eye disease (TED), sponsored by Viridian Therapeutics. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
veligrotug
03
Conditions
thyroid eye disease (TED)
Beyond the preview
Go deeper on NCT07832136.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07832136.